Business Context and Reporting Period
This Form 8-K was filed by AgeX Therapeutics, Inc. (referred to as "AgeX") on March 11, 2019. The report details executive compensation adjustments approved by the Board of Directors on the same date. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes and Compensation Details
The Board approved cash bonuses, equity awards, and salary increases for specific officers:
- Michael D. West (CEO): Received 100,000 stock options and 50,000 Restricted Stock Units (RSUs). No cash bonus was awarded. His annual salary was increased to $544,688.
- Hal Sternberg (VP-Research): Received a $25,000 cash bonus and 15,000 stock options. No RSUs were awarded. His annual salary was increased to $251,127.
- General Staff: A 3.75% salary increase was approved for all officers and employees.
Equity Terms:
- Stock Options: Granted under the 2017 Equity Incentive Plan with an exercise price of $4.28 per share. Vesting is 25% after one year, with the remainder vesting monthly over 36 months. Options expire 10 years from the grant date.
- RSUs: Granted to Dr. West only. Vesting is 25% after one year, with the remainder vesting quarterly over 12 months. Settlement may be in stock or cash at the company's election.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to risk factors detailed in other SEC filings. No specific business guidance, outlook, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2017 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the current fair market value of AgeX common stock relative to the $4.28 exercise price of the new options.
- Review the company's cash position to ensure liquidity is sufficient to cover the $25,000 cash bonus and potential cash settlement of RSUs.
- Check subsequent filings for any changes in executive employment status that could trigger accelerated vesting or option expiration.